Drug Profile
Research programme: spleen tyrosine kinase inhibitors - HUTCHMED
Alternative Names: HMPL-281Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Hutchison MediPharma
- Class Small molecules
- Mechanism of Action Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunological disorders; Inflammation
Most Recent Events
- 09 Jun 2021 Hutchison MediPharma has been acquired and merged into HUTCHMED
- 28 Jan 2018 No recent reports of development identified for preclinical development in Immunological-disorders in China (PO)
- 28 Jan 2018 No recent reports of development identified for preclinical development in Inflammation in China (PO)